Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nemametrix Inc. oversees a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 2 pending office actions. These 2 pending office actions are situated in 2 distinct art units, suggesting that the company's research and development efforts cover different specialized technical fields within the biotechnology sector.
There are 2 distinct examiners assigned to the portfolio's current workload. SPENCER, ANDREA LYNNE MORRIS is the busiest examiner and is responsible for 1 busiest examiner pending action. This indicates that the workload is distributed among the 2 distinct examiners, creating a balanced prosecution environment for the company's pending matters.
The involvement of 2 distinct art units requires the practitioner to address the specific examination standards of each unit. Because there are different examiners, the company must manage separate prosecution tracks. This Biotechnology & Pharmaceuticals portfolio benefits from having more than one point of contact, which may provide different insights into the patentability of the company's innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCER, ANDREA LYNNE MORRIS | 1 | 20.0% | +37.5% |
| SMALL, KATHERINE R | 1 | 69.4% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787899 | MODEL ORGANISMS HUMANIZED FOR DRUG DISCOVERY AND SCREENING | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787899 | MODEL ORGANISMS HUMANIZED FOR DRUG DISCOVERY AND SCREENING | SPENCER, ANDREA LYNNE MORRIS | — |
| 17266592 | Homologous Recombination Reporter Construct and Uses Thereof | SMALL, KATHERINE R | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17787899 | MODEL ORGANISMS HUMANIZED FOR DRUG DISCOVERY AND SCREENING | SPENCER, ANDREA LYNNE MORRIS | 1631 | §101§102§103DP | Final Rejection | — | Pending | Jun 21, 2022 |
| 17266592 | Homologous Recombination Reporter Construct and Uses Thereof | SMALL, KATHERINE R | 1633 | — | Final Rejection | — | Pending | Feb 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNemametrix Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrea Lynne Morris Spencer has the most, with 1 of Nemametrix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
